검색어: klopidogrelu (슬로베니아어 - 영어)

incidenca hujših primerov krvavitev je bila pri klopidogrelu 1,4%%, pri asa pa1,6%%.
the incidence of severe cases was 1.4% for clopidogrel and 1.6% for asa.

ker kliničnih podatkov o izpostavljenosti klopidogrelu med nosečnostjo ni, je potrebna previdnost, zato se uporabo klopidogrela med nosečnostjo odsvetuje.
as no clinical data on exposure to clopidogrel during pregnancy are available, it is preferable not to use clopidogrel during pregnancy as a precautionary measure.

ker kliničnih podatkov o izpostavljenosti klopidogrelu med nosečnostjo ni, je kot previdnostni ukrep zaželeno, da se klopidogrela v nosečnosti ne uporablja.
as no clinical data on exposure to clopidogrel during pregnancy are available, it is preferable not to use clopidogrel during pregnancy as a precautionary measure.

< 50 x 109/l), potreba po klopidogrelu ali peroralnih antikoagulantih ali intoleranca za katero od obeh snovi.
6 months; prior intracerebral hemorrhage; significant thrombocytopenia (platelet count < 50 x 109/l); requirement for clopidogrel or oral anticoagulants (oac); or intolerance to any of the two compounds.

posledično so trombociti, ki so bili izpostavljeni klopidogrelu, prizadeti preostanek svoje življenske dobe in okrevanje trombocitov se pojavlja s hitrostjo, ki je v skladu s trombocitno premeno.
consequently, platelets exposed to clopidogrel are affected for the remainder of their lifespan and recovery of normal platelet function occurs at a rate consistent with platelet turnover.

zlasti post hoc analiza podatkov 2.172 bolnikov (17 % celotne populacije cure), ki so jim namestili žilno opornico (stent-cure), je ob klopidogrelu v primerjavi s placebom pokazala značilno, 26,2 % zmanjšanje rt za sestavljen primarni opazovani dogodek (srčno- žilna smrt, miokardni infarkt, možganska kap) in tudi značilno, 23,9 % zmanjšanje rt za drug sestavljen primarni opazovani dogodek (srčno-žilna smrt, miokardni infarkt, možganska kap ali neodzivna ishemija).
in particular, in a post-hoc analysis in 2,172 patients (17% of the total cure population) who underwent stent placement (stent-cure), the data showed that clopidogrel compared to placebo, demonstrated a significant rrr of 26.2% favouring clopidogrel for the co-primary endpoint (cv death, mi, stroke) and also a significant rrr of 23.9% for the second co-primary endpoint (cv death, mi, stroke or refractory ischaemia).